Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsChing-Juh Lai, Michael Bray, Alexander G. Pletnev, Ruhe Men, Yi-Ming Zhang, Kenneth H. Eckels, Robert M. Chanock
Estimating the term…
The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.
A recombinant genetic construct, adapted to encode a chimeric flaviviral genome, comprising:
A chimeric virus having a genome comprising:
An isolated recombinant DNA construct that encodes stable, full-length infectious dengue type 4 viral RNA.
An immunogenic composition against dengue type 4 virus comprising a dengue type 4 virus, having a stable, full-length infectious dengue type 4 viral genome comprising at least one mutation that is introduced into the viral genome, and a pharmaceutically acceptable carrier.
An isolated RNA segment comprising stable, full-length infectious dengue type 4 viral genome transcribed from a recombinant DNA construct.
A baculovirus, comprising:
An immunogenic composition consisting essentially of dengue type 4 virus envelope glycoprotein and NS1 nonstructural protein.
An immunogenic composition consisting essentially of dengue type 4 virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 nonstructural protein.
A baculovirus comprising the dengue cDNA coding sequence for:
An immunogenic composition consisting essentially of:
A method for producing an immunogenic composition, comprising:
A baculovirus comprising the Japanese B encephalitis virus cDNA coding sequence for the 3 structural proteins (C-M-E) and non-structural proteins NS1 and NS2a.
A method for producing an immunogenic composition, comprising:
Dependencies are inferred from the claim text.